More Videos
SPECIAL REPORT
MOST SHARED
- Kuoni CEO Sees Recovery in Travel Sector
- Gold Retreats from Record High as Dollar Rebounds
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- Chinese Overcapacity is Worsening, EU Chamber Warns
- China Unveils Carbon Target Ahead of Copenhagen
- Euro Shares Record Biggest Drop in 7 Months
- Wal-Mart Price Pressure Hurts China Workers: Report
- Great Britain, No Longer That Great: Investor
- Fannie Mae to Tighten Lending Standards: Report
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- US Dollar Falls to 14-Year Low Against the Yen
- US Companies Already Moving on Curbing Emissions
- Fannie Mae to Tighten Lending Standards: Report
- Investing in Good Karma – and Making a Profit
- Retailers Should Believe in Christmas Miracles
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- Lloyds Gets OK for Record $22.5 Billion Rights Issue
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
After a 2 a.m. start today, I thought I was done with work for the week and I was already cruising into the weekend. But, for this, I don't mind spending some time working from home on a Friday afternoon.
 |
Source: universityofcalifornia.com Dr. Susan Desmond-Hellmann |
], Dr. Susan Desmond-Hellmann may be headed out the door sooner than anyone thought. She's the company's President of Product Development and the one who many credit as being the driving force behind Genentech's successful drug development track record over the past several years. As one veteran biotech analyst once told me, "No one knows how to design oncology clinical trials better than Sue." I've always thought her third act (she was a practicing oncologist before going corporate) would be as the CEO of a big pharma. Her name was always on the rumored shortlist when spots opened up in recent years. But I was wrong. She's taking the untold millions of dollars she made at Genentech and appears to be going to the much lower-paying world of academia. You had to know something was up, perhaps, when Roche announced a management shakeup at Genentech and moved the good doctor into an "advisory role."
The University of California system this afternoon issued this press release announcing that Dr. Desmond-Hellmann has been nominated to be the next Chancellor of UC San Francisco. The UC Board of Regents will decide whether to approve her for the position at its meeting next week. If the board hires Dr. Desmond-Hellmann, she'd take over the campus, known for its clinical research, on August 3rd.
She's quoted in the press release as saying, "I began my career at UCSF, and my heart has never left it. I am delighted and humbled to have the Regents' consideration for the position of chancellor at this truly great institution. My life's work has been focused on making a difference for patients, and I cannot think of a better place than UCSF to carry that work forward." Well, I can, but USC isn't looking for a new president.
Anyway, the UC says the Regents will talk about salary behind closed doors and then vote on it in public. I'm almost certain she doesn't need the money and isn't doing it for that.
I hope she won't mind, but I wanted to share an email Dr. Desmond- Hellmann sent me last month in response to this blog that I did the day Genentech formally became apart of Roche.
"Your...blog...was incredibly touching to me," she wrote. "(It) was a reminder to me of why I am consistently inspired to try to do a better job, as too many patients need better therapies. So I am writing to convey a big thanks to you for the kind words and for capturing some of the spirit of why being in biotech (and hopefully covering it) is special beyond the business aspect."
I don't think you'll need it, but good luck next week, Sue. UCSF will be fortunate to have you.
Now, back to starting my weekend. No more work, alright?
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes